| answer text |
<p>Prior to the establishment of the National Institute for Health Research (NIHR)
in April 2006, the main part of the total health research expenditure of the Department
of Health was devolved to and managed by National Health Service organisations. The
NHS organisations reported on their use of these allocations in annual research and
development reports. These reports identify total, aggregated expenditure on national
priority areas, including cancer. They do not provide details of research into particular
cancer sites. From April 2006 to March 2009, transitional research funding was allocated
to these organisations at reducing levels. At the same time, an increasing amount
of NHS research funding was awarded competitively through new NIHR programmes and
schemes.</p><p> </p><p> </p><p> </p><p>Expenditure by the NIHR through research programmes,
research centres and units, and research training awards on mesothelioma research
is shown in the following table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>2006-07</p><p>£
million</p></td><td><p>2007-08</p><p>£ million</p></td><td><p>2008-09</p><p>£ million</p></td><td><p>2009-10</p><p>£
million</p></td><td><p>2010-11</p><p>£ million</p></td><td><p>2011-12</p><p>£ million</p></td><td><p>2012-13</p><p>£
million</p></td><td><p>2013-14</p><p>£ million</p></td></tr><tr><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.4</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>Total spend by the NIHR on mesothelioma research is higher
than this because expenditure by the NIHR Clinical Research Network (CRN) on this
topic cannot be disaggregated from total CRN expenditure.</p><p> </p><p> </p><p> </p><p>The
NIHR invests in infrastructure for experimental medicine to translate scientific developments
into benefits for patients. This infrastructure includes biomedical centres and units,
clinical research facilities, and experimental cancer medicine centres. The NIHR Biomedical
Research Centre at University College London Hospitals NHS Foundation Trust and University
College London has contributed to the funding of recent research on the use of TRAIL
(tumour necrosis factor-related apoptosis-inducing ligand)-expressing mesenchymal
stem cells to reduce tumour growth in malignant mesothelioma.</p><p> </p><p> </p><p>
</p><p>The following table provides expenditure by the Medical Research Council on
research related to mesothelioma over the past six years. Information on spend from
2004-05 to 2007-08 was not available within the timescale.</p><p> </p><p> </p><p>
</p><table><tbody><tr><td><p>2008-09</p><p>£ million</p></td><td><p>2009-10</p><p>£
million</p></td><td><p>2010-11</p><p>£ million</p></td><td><p>2011-12</p><p>£ million</p></td><td><p>2012-13</p><p>£
million</p></td><td><p>2013-14</p><p>£ million</p></td></tr><tr><td><p>0.9</p></td><td><p>0.8</p></td><td><p>1.7</p></td><td><p>2.4</p></td><td><p>2.2</p></td><td><p>1.7</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>In April 2014, I convened a high level meeting between the
Association of British Insurers and the British Lung Foundation (BLF) to discuss how
insurers can remain engaged in support for mesothelioma research. Two insurers – Aviva
and Zurich – who participated in the earlier donation by insurers of £3 million to
the BLF, have agreed to each donate £250,000 per annum to the BLF for mesothelioma
research over the next two years – a combined total of £1 million.</p><p> </p>
|
|
